Merger with IRRAS
ClearPoint Neuro announced a merger agreement with IRRAS, expected to close in Q4 2025. The merger provides access to a $0.5 billion market in intracranial fluid management and expands the commercial team by over 40 professionals.
Revenue Growth
ClearPoint Neuro reported a 9% increase in total revenue for Q3 2025, reaching $8.9 million compared to $8.1 million in Q3 2024.
Neurosurgery Navigation Revenue Increase
The neurosurgery navigation segment grew by 20% to $3.4 million in Q3 2025, driven by higher sales of PRISM Laser Therapy and the introduction of new navigation software.
Capital Equipment and Software Growth
Revenue from capital equipment and software increased by 25% to $1 million in Q3 2025.
Increased Gross Margin
Gross margin improved to 63% in Q3 2025 from 60% in Q3 2024.
Strong Cash Position
ClearPoint Neuro's cash and cash equivalents increased to $38.2 million as of September 30, 2025, up from $20.1 million at the end of 2024.
New CRO Facility
ClearPoint transitioned to a new CRO facility in Torrey Pines, expected to lead to double-digit growth in biologics and drug delivery in Q4 2025 and beyond.